Design of therapeutic proteins with enhanced stability

Therapeutic proteins such as antibodies constitute the most rapidly growing class of pharmaceuticals for use in diverse clinical settings including cancer, chronic inflammatory diseases, kidney transplantation, cardiovascular medicine, and infectious diseases. Unfortunately, they tend to aggregate when stored under the concentrated conditions required in their usage. Aggregation leads to a decrease in antibody activity and could elicit an immunological response. Using full antibody atomistic molecular dynamics simulations, we identify the antibody regions prone to aggregation by using a technology that we developed called spatial aggregation propensity (SAP). SAP identifies the location and size of these aggregation prone regions, and allows us to perform target mutations of those regions to engineer antibodies for stability. We apply this method to therapeutic antibodies and demonstrate the significantly enhanced stability of our mutants compared with the wild type. The technology described here could be used to incorporate developability in a rational way during the screening of antibodies in the discovery phase for several diseases.

[1]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[2]  J. Alderfer,et al.  Energy transduction during catalysis by Escherichia coli DNA photolyase. , 1992, Biochemistry.

[3]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[4]  K. Dill.  Dominant forces in protein folding. , 1990, Biochemistry.

[5]  A. Lesk,et al.  Conformations of immunoglobulin hypervariable regions , 1989, Nature.

[6]  M Goodall,et al.  The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. , 2000, Molecular immunology.

[7]  D. Mould,et al.  Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modifications. , 1991, Analytical biochemistry.

[8]  W. Delano,et al.  Convergent solutions to binding at a protein-protein interface. , 2000, Science.

[9]  F. Cohen,et al.  Thermodynamics of model prions and its implications for the problem of prion protein folding. , 1999, Journal of molecular biology.

[10]  D. Thirumalai,et al.  Exploring protein aggregation and self‐propagation using lattice models: Phase diagram and kinetics , 2002, Protein science : a publication of the Protein Society.

[11]  D. Thirumalai,et al.  Dissecting the assembly of Abeta16-22 amyloid peptides into antiparallel beta sheets. , 2003, Structure.

[12]  Steven J Shire,et al.  Challenges in the development of high protein concentration formulations. , 2004, Journal of pharmaceutical sciences.

[13]  L. Serrano,et al.  Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins , 2004, Nature Biotechnology.

[14]  D. Covell,et al.  A role for surface hydrophobicity in protein‐protein recognition , 1994, Protein science : a publication of the Protein Society.

[15]  S. Demarest,et al.  A broad range of Fab stabilities within a host of therapeutic IgGs. , 2007, Biochemical and biophysical research communications.

[16]  V. Abramov,et al.  Investigation of the cooperative structure of Fc fragments from myeloma immunoglobulin G. , 1998, Biochemistry.

[17]  Amedeo Caflisch,et al.  Computational models for the prediction of polypeptide aggregation propensity. , 2006, Current opinion in chemical biology.

[18]  Colleen E. Price,et al.  Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[19]  P. Chakrabarti,et al.  Conservation and relative importance of residues across protein-protein interfaces , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[21]  Sarah A. Teichmann,et al.  Principles of protein-protein interactions , 2002, ECCB.

[22]  Saurabh Aggarwal,et al.  What's fueling the biotech engine? , 2007, Nature Biotechnology.

[23]  Huub Schellekens,et al.  Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.

[24]  Dusan Bratko,et al.  Protein aggregation in silico. , 2007, Trends in biotechnology.

[25]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.

[26]  R. Broglia,et al.  Folding and aggregation of designed proteins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[28]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[29]  M Levitt,et al.  Simulating the minimum core for hydrophobic collapse in globular proteins , 1997, Protein science : a publication of the Protein Society.

[30]  Kevin J. Naidoo,et al.  Carbohydrate solution simulations: Producing a force field with experimentally consistent primary alcohol rotational frequencies and populations , 2002, J. Comput. Chem..

[31]  A R Rees,et al.  WAM: an improved algorithm for modelling antibodies on the WEB. , 2000, Protein engineering.

[32]  A. Caflisch,et al.  The role of side-chain interactions in the early steps of aggregation: Molecular dynamics simulations of an amyloid-forming peptide from the yeast prion Sup35 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Dobson,et al.  Rationalization of the effects of mutations on peptide andprotein aggregation rates , 2003, Nature.

[34]  Amedeo Caflisch,et al.  Prediction of aggregation rate and aggregation‐prone segments in polypeptide sequences , 2005, Protein science : a publication of the Protein Society.

[35]  C. Hall,et al.  Molecular dynamics simulations of spontaneous fibril formation by random-coil peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[37]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[38]  Garrett M. Morris,et al.  Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.

[39]  A. Lesk,et al.  Standard conformations for the canonical structures of immunoglobulins. , 1997, Journal of molecular biology.

[40]  Jianpeng Ma,et al.  Molecular dynamics analysis of a buckyball–antibody complex , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Thirumalai,et al.  Dissecting the Assembly of Aβ16–22 Amyloid Peptides into Antiparallel β Sheets , 2003 .

[42]  V. Ingram,et al.  Gene Mutations in Human Hæmoglobin: the Chemical Difference Between Normal and Sickle Cell Hæmoglobin , 1957, Nature.

[43]  Jochem Alsenz,et al.  Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice , 1997, Pharmaceutical Research.

[44]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[45]  C. Chothia,et al.  The atomic structure of protein-protein recognition sites. , 1999, Journal of molecular biology.

[46]  D. J. Harrington,et al.  The high resolution crystal structure of deoxyhemoglobin S. , 1997, Journal of molecular biology.